Ravelcare Ltd has launched its 'Ravel PRO' hair and skincare range, securing a 20% revenue contribution in its first full month. While the company remains debt-free, management has deferred its manufacturing plant project, keeping IPO funds in fixed deposits. Investors are watching the firm’s pivot to technology-led growth with an AI-diagnostic skincare line planned for H2 FY27.
Ravelcare Expansion: New Launch and IPO Fund Strategy
Revenue grew by 7.9% to Rs 26.95 crore in FY26; Ravel PRO contributed 20% of revenue in July.
Reader Takeaway: Strong revenue growth from new launches is offset by concerns over delayed IPO-funded capital expenditure.
What just happened
Ravelcare Ltd has rolled out 'Ravel PRO', a new range of twelve dermatologist-developed hair and skincare products. The products are currently live across major e-commerce platforms like Amazon, Nykaa, and Blinkit, as well as quick-commerce channels. The launch resulted in a 20% incremental revenue boost during July, marking the brand's shift into broader omni-channel distribution.
Why this matters
The successful adoption of the Ravel PRO range signals that the company is diversifying its revenue streams beyond its legacy portfolio. Furthermore, the company has announced plans to enter the AI-diagnostic skincare space in H2 FY27, aiming to shift from simple product sales to tech-enabled, photo-based skin diagnostics.
The backstory
Ravelcare concluded its IPO in December 2025, raising Rs 24.10 crore to fund backward integration via a new manufacturing unit. However, management has paused this construction to ensure that the new product lines stabilize before committing to large-scale infrastructure. The funds raised are currently held in bank fixed deposits.
Financial performance
In FY26, the company posted a revenue of Rs 26.95 crore and a profit after tax of Rs 5.15 crore. The company maintains a healthy net worth of Rs 37.41 crore and continues to operate as a debt-free entity.
Risks to watch
Investors should monitor the potential impact of delayed capital expenditure. The decision to hold back on the manufacturing plant while keeping IPO funds idle in bank deposits remains a key governance point. Additionally, the execution of the AI-diagnostic roadmap in FY27 is a critical milestone for future valuation.
What to track next
Watch for management updates on the revised timeline for the in-house manufacturing facility and any further performance metrics for the Ravel PRO range in the coming quarters.